Payment overview · 2025
General Payments
$551.11
13 reported records · 8 companies
Healthcare provider profile · identity verified
Matthew K Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · POULSBO, WA · NPI 1437312709
Verified facts
What the public records show
CMS Open Payments records show Matthew K Johnson, MD received $551.11 in general payments during 2025 across 13 reported records.
Abbott Laboratories accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $187.65 | 34.0% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $127.34 | 23.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $123.05 | 22.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $48.27 | 8.8% | 3 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $21.91 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.40 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.89 | 2.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.60 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $537.22 | 12 |
| Education | $13.89 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $187.65 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $123.05 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $48.27 | 3 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 343 | 90 |
| Lisinopril | Lisinopril | 295 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 50 |
| Losartan Potassium | Losartan Potassium | 189 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 47 |
| Gabapentin | Gabapentin | 164 | 49 |
| Omeprazole | Omeprazole | 148 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 39 |
| Simvastatin | Simvastatin | 131 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 32 |
| Meloxicam | Meloxicam | 121 | 44 |
| Allopurinol | Allopurinol | 114 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 20 |
| Metformin Hcl | Metformin Hcl | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 84 | 16 |
| Trazodone Hcl | Trazodone Hcl | 84 | 20 |
| Finasteride | Finasteride | 82 | 22 |
| Diazepam | Diazepam | 80 | 11 |
| Sertraline Hcl | Sertraline Hcl | 80 | 17 |
| Tramadol Hcl | Tramadol Hcl | 78 | 15 |
| Alprazolam | Alprazolam | 76 | 17 |
| Potassium Chloride | Potassium Chloride | 66 | 18 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Eliquis | Apixaban | 59 | 16 |
| Furosemide | Furosemide | 59 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 15 |
| Baclofen | Baclofen | 58 | 21 |
| Aripiprazole | Aripiprazole | 56 | 13 |
| Metformin Hcl Er | Metformin Hcl | 56 | 14 |
| Ozempic | Semaglutide | 53 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 14 |
| Bupropion Xl | Bupropion Hcl | 47 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 13 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 11 |
| Xarelto | Rivaroxaban | 38 | 15 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 11 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | 11 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | 11 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Prednisone | Prednisone | 25 | 14 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Nucynta | Tapentadol Hcl | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $551.11 · 13 records | Abbott Laboratories | FREESTYLE LIBRE 3, JARDIANCE, REXULTI, SPRINT PNS System, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error